Official Journal
of the European Union

EN
L series

2026/2526

16.11.2026

COMMISSION IMPLEMENTING REGULATION (EU) 2026/2526

of 13 November 2026

cancelling the Union authorisation for the single biocidal product 'Manorapid express GEL' in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council and repealing Commission Implementing Regulation (EU) 2023/1106

(Text with EEA relevance)

THE EUROPEAN COMMISSION,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products ([1]), and in particular Article 49 thereof,

Whereas:

(1) On 6 June 2023, Commission Implementing Regulation (EU) 2023/1106 ([2]) granted a Union authorisation with the authorisation number EU-0027675-0000 to the authorisation holder Lysoform Dr Hans Rosemann GmbH for the making available on the market and use of the same single biocidal product containing Propan-1-ol and Propan-2-ol 'Manorapid express GEL' in accordance with Article 44(5), first subparagraph, of Regulation (EU) No 528/2012.

(2) On 23 July 2026, Lysoform Dr Hans Rosemann GmbH submitted to the European Chemicals Agency ('the Agency') a request to cancel that Union authorisation in accordance with Article 49 of Regulation (EU) No 528/2012. The request was recorded under case number BC-JE120148-56 in the Register for Biocidal Products.

(3) On 15 September 2026, Lysoform Dr Hans Rosemann GmbH submitted a reasoning for the request for cancellation, providing that it had decided to discontinue the production of 'Manorapid express GEL' based on commercial considerations.

(4) On 16 September 2026, the Agency forwarded the reasoned request to the Commission.

(5) It is therefore appropriate to cancel the Union authorisation for the single biocidal product 'Manorapid express GEL' at the reasoned request of the authorisation holder and consequently to repeal Implementing Regulation (EU) 2023/1106.

(6) It is also appropriate to grant a period of grace for the making available on the market and the use of the existing stocks of 'Manorapid express GEL' in accordance with Article 52 of Regulation (EU) No 528/2012,

HAS ADOPTED THIS REGULATION:

Article 1

The Union authorisation for the single biocidal product 'Manorapid express GEL' granted by Implementing Regulation (EU) 2023/1106 to Lysoform Dr Hans Rosemann GmbH with the authorisation number EU-0027675-0000 is cancelled.

([1]) OJ L 167, 27.6.2012, p. 1, ELI: http://data.europa.eu/eli/reg/2012/528/oj.

([2]) Commission Implementing Regulation (EU) 2023/1106 of 6 June 2023 granting a Union authorisation for the single biocidal product 'Manorapid express GEL' in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council. (OJ L 147, 7.6.2023, p. 76, ELI: http://data.europa.eu/eli/reg_impl/2023/1106/oj).

Article 2

Implementing Regulation (EU) 2023/1106 is repealed.

Article 3

The biocidal product 'Manorapid express GEL' shall no longer be made available on the market from 6 June 2027 and existing stocks of such biocidal product shall no longer be used from 6 December 2027.

Article 4

This Regulation shall enter into force on the twentieth day following that of its publication in the *Official Journal of the European Union*.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 13 November 2026.

For the Commission
The President
Ursula VON DER LEYEN